Intradermal botulinum toxin type A injection effectively reduces residual limb hyperhidrosis in amputees: a case series.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 18586144.
- Also identified by DOI 10.1016/j.apmr.2007.11.054.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To study the effectiveness of botulinum toxin type A (BTX-A) therapy for residual limb hyperhidrosis, prosthesis fit and function, and residual and phantom limb pain in patients with limb amputation. Consecutive case series. Outpatient physical medicine and rehabilitation clinic. Walter Reed Army Medical Center patients (N=8) with unilateral traumatic upper- or lower-limb amputation. BTX-A was injected transdermally in a circumferential pattern around the residual limb by using a 1-cm matrix grid. A 10-cm continuous Likert visual analog scale was used to assess residual limb sweating and pain and prosthesis fit and function before and 3 weeks after BTX-A injections. Patients reported a significant reduction in sweating and improvement in prosthesis fit and function after treatment. However, residual limb and phantom pain were unaffected by treatment. BTX-A may be an effective treatment for residual limb hyperhidrosis, resulting in subjective improvement in prosthesis fit and functioning. BTX-A should be considered as a method to manage excessive sweating in the residual limb of traumatic amputees.
Medical subject headings
- Amputation Stumps
- Amputees
- Botulinum Toxins, Type A
- Hyperhidrosis
- Neuromuscular Agents
- Phantom Limb